全球CAR-T細胞療法市場：市場規模、預測、臨床試驗與趨勢（2026-2027）

CAR-T 報告執行摘要

CAR-T細胞療法是癌症治療領域的突破性進展，也是患者極具前景的治療選擇。這種免疫療法利用人體自身的免疫細胞，在實驗室中進行改造，增強其辨識和摧毀癌細胞的能力。當再次輸注到患者體內時，這些經過改造的細胞會在體內增殖，如同「活體藥物」一般持續對抗癌症。

全球核准情況

自 2017 年以來，已有 16 種 CAR-T 細胞療法在多個醫療市場商業化，高於前一年的 13 種。其中 7 種已獲得美國食品藥物管理局(FDA) 的批准。這些療法包括：

• 1. Kymriah (Tisagenrekresel)
• 2. Yescata (Axicaptadiene siroylosell)
• 3.Tekartus（brexcabutagen autoleucel）
• 4. Breyange（lysocabtadiene malaryl sel）
• 5.阿貝庫瑪（Idekabutagene vikrussel）
• 6.Carvicti（Siltakabutadiene autoleucel）
• 7. Aucatzel（Obekabutadiene autoleucel）

在美國以外，中國國家藥品監督管理局（NMPA）已批准了六種 CAR-T 療法（Cultiva、Ikaida、Zevol-Cel、Yorwida、Fukaso 和 Saturi-Cel），其中包括 Saturi-Cel，它是世界上第一個獲得監管部門批准的用於治療固體癌的 CAR-T 細胞療法。

此外，NexCAR19 和 Qartemi 兩種療法已獲得印度中央藥品標準與監管局 (CDSCO) 的批准。在全球方面，韓國食品藥物安全部 (MFDS​​) 批准了 RIMQARTO，這是韓國首個國產 CAR-T 療法，標誌著 CAR-T商業性市場進入了一個全新的監管領域。

CAR-T市場擴張與產業成長

這些監管部門的批准標誌著一個重要的里程碑，鞏固了CAR-T市場在生物技術領域的重要地位。併購活動進一步加速，展現出投資者強勁且不斷成長的信心。一系列影響深遠的交易，包括Celgene以90億美元收購Juno Therapeutics，隨後Bristol-Myers Squibb以740億美元收購Celgene，Gilead以119億美元收購Kite Pharma，以及Astellas Pharma以6.65億美元收購Xyphos Biosciences，都已確立了CAR-T-T作為大型製藥企業必備的地位。

這股勢頭絲毫沒有減弱的跡象。僅自2024年以來，就已達成超過80億美元的額外許可協議和收購，其中包括艾伯維收購Capstan Therapeutics、羅氏收購Poseida Therapeutics以及百時美施貴寶收購Orbital Therapeutics，製藥巨頭們競相獲取下一代平台技術。這些交易凸顯了大型製藥企業日益重視對CAR-T技術的投資，並致力於塑造癌症治療的未來。

隨著CAR-T療法的不斷發展，該產業面臨許多關鍵挑戰，例如提高基因轉移效率和降低毒性風險。研究人員正在積極探索CRISPR和電穿孔技術以增強T細胞的修飾，而另一些研究人員則致力於開發控制CAR-T細胞活性的「開關」。

長期以來，固體癌的治療一直是最大的挑戰之一。臨床試驗表明，實體瘤的治療反應率低於血液腫瘤。然而，這種情況正在改變。目前，已有近290項固體癌臨床試驗正在進行中，而沙曲唑在中國的核准也證明，這項障礙已不再是不可逾越的。為了進一步提高固體癌的治療效果，識別固體癌特異性抗原仍是研究的重點。

除了腫瘤領域，CAR-T療法產業也積極拓展自體免疫疾病領域。目前，已有超過250項正在進行的臨床試驗，探索CAR-T療法在全身性紅斑性狼瘡（SLE）、系統性硬皮症和多發性硬化症等疾病的應用潛力。早期數據顯示，部分患者無需藥物治療即可達到緩解。

目前，市面上大多數CAR-T療法和正在進行的臨床試驗都依賴自體（患者來源）細胞。然而，下一個突破在於異體CAR-T療法。這種「現成」的解決方案有望簡化生產流程、降低成本並擴大患者群體。

全球CAR-T細胞療法市場

CAR-T細胞療法市場已從早期的實驗性療法發展成為一個全球性的數十億美元產業。在血液腫瘤治療領域取得的早期成功為其更廣泛的應用鋪平了道路，眾多公司，從新創公司到生物技術巨頭，都在致力於拓展這一領域。隨著創新不斷湧現，CAR-T療法的未來蘊藏著巨大的潛力，可望徹底改變全球癌症治療模式。

本報告提供了以下見解：

• 本次演講將概述 CAR-T 療法的歷史沿革，重點介紹其從 1989 年至今的發展歷程、進一步變革的潛力以及 CAR-T 領域活動的加速發展。
• 自體和異體 CAR-T 細胞療法的研發相關的生產流程和成本進行分析。
• CAR-T細胞標靶的癌症生物標記和抗原概述。
• 對全球 CAR-T 專利格局進行詳細分析，包括主要申請人、發明人和地區。
• 本次演講將深入探討使用 CAR-T 細胞的臨床試驗的實施率、類型和趨勢，包括自體免疫。
• 對 CAR-T 細胞療法相關科學論文的發表頻率和類型進行綜述。
• 美國國立衛生研究院 (NIH) 授予的用於支持 CAR-T 細胞療法研究的撥款津貼。
• CAR-T 產業貿易趨勢與策略夥伴關係概述。
• 本書提供了全球核准的所有 16 種 CAR-T 療法的解釋，包括 Kymriah、Yescarta、Tecartus、Breyanzi、 說明、Carvykti、Aucatzyl、Carteyva、Yikaida、Zevor-cel、Yorwida、Fucaso、Satri-cel、NexCAR19、Qartex 和 RQOat。
• 回顧美國 CAR-T 療法的報銷政策和歐洲基於結果的報銷政策。
• 依地區、產品和適應症對 CAR-T 細胞療法進行全球市場分析。
• 對 CAR-T 細胞療法市場 170 多家主要競爭對手進行了介紹（包括新產品、有前景的候選藥物和專有技術平台）。
• 此外，還包含許多其他資訊。

本報告解答的主要問題：

• 目前已獲FDA已通過核准的CAR-T療法有哪些特色？哪些公司生產這些療法，哪些公司分銷這些療法？
• CAR-T領域未來有哪些發展前景？
• 預計近期將有哪些新的CAR-T產品進入市場？
• 目前有多少套自動化製造系統可用於CAR-T細胞療法的生產？
• 在惡性腫瘤（體液腫瘤和固體癌）中，最常被標靶的抗原是什麼？
• 從 2012 年至今，與 CAR-T 相關的專利申請和專利註冊數量是多少？
• 哪個國家擁有最多的CAR-T專利？
• 哪家公司提交的CAR-T相關專利申請最多？
• 您認為誰是CAR-T專利的主要發明者？
• 從2003年至今，共註冊了多少篇與CAR-T相關的臨床試驗？
• CAR-T細胞臨床試驗中最常使用的生物標記抗原有哪些？
• 過去兩年簽署了多少份與 CAR-T 相關的合約？哪些公司簽署了這些合約？
• 目前全球核准的CAR-T療法市場規模有多大？
• 有哪些有希望在不久的將來實現商業化的CAR-T候選藥物？
• 美國和歐洲如何處理 CAR-T 療法的保險報銷問題？
• 依地區、產品和適應症分類，CAR-T療法的市場規模是多少？
• 哪些公司是目前領先的CAR-T細胞療法研發企業？
• 它還包含許多其他資訊。

利用這份全球策略報告，您可以：

• 充分利用快速湧現的趨勢
• 決策最佳化
• 降低企業風險
• 聯繫合作夥伴和投資者，尋求合作和資金籌措。
• 2035年以後，我們將繼續實施明智且有利的商業策略。

全球市場競爭異常激烈，留給市場研究的時間非常有限。取得這份報告，幫助您掌握最新動態，避免錯失關鍵機會。

提及的公司和組織

諾華、吉利德科學、Kite Pharma、百時美施貴寶、2seventy bio、傳奇生物、強生製藥、Autolus Therapeutics、JW Therapeutics、復星醫藥、CARsgen Therapeutics、IASO Biotherapeutics、Immuneel Therapeutics、ImmunoACT、Curocell、ATech、alk、Techk、Techk、Tech、Yia Biotechnology、Arcellx、Allogene Therapeutics、Caribou Biosciences、CRISPR Therapeutics、Intellia Therapeutics、Precision Biosciences、Century Therapeutics、Fate Therapeutics、Beam Therapeutics、Editas Medicine、Cartesian Therapeutics、Kyeuk、Traputics Therapy​​ans Medicine、Badian Therapeutics Therapy​​an Therapyrap Biopharma、Lyell Immunopharma、Mustang Bio、Vor Biopharma、Gracell Biotechnologies、Poseida Therapeutics、Adicet Bio、Atara Biotherapeutics、Cellectis、Celyad Oncology、Wugen、Strand Therapeutics、Wayphos Bio、Kelonia Therapeutics、Xscienceer、Ysciences BioXsciences BioXsciences BioXsciences BioXsciences BioXsciences BioXsciences BioXsciences BioXsciences BioXsciences Bio草Biomedicine、MaxCyte、Thermo Fisher Scientific、Terumo BCT 等 112 家公司。

關於出版商

我們公司成立於2006年，是全球首家也是唯一一家專注於幹細胞產業的市場研究公司。公司總部位於華盛頓特區附近，鄰近美國食品藥物管理局（FDA）、國立衛生研究院（NIH）和美國國會大廈。 20多年來，我們一直追蹤這個市場，開發專有資料集，提取趨勢數據，並進行人工智慧無法提供的產業訪談。

迄今為止，我們的研究成果已被《華爾街日報》、《美國血庫協會》（AABB）和《日誌》等刊物引用，並被托尼·羅賓斯在其暢銷書《生命力》（LifeForce）中提及。目前，我們經營全球最大的幹細胞產業新聞網站，每年吸引近百萬讀者。

我們為 GE Healthcare、輝瑞和高盛等財富 500 強企業提供服務，並且是幹細胞和細胞治療行業數據領域的全球領導者。

第1章：報告概述

第2章 CAR-T細胞療法和CAR-T技術

• CAR-T細胞的結構
• 將T細胞轉化為CAR-T細胞
• 第五代CAR-T細胞
  • 第一代CAR-T
  • 第二代CAR-T
  • 第三代CAR-T療法
  • 第四代CAR-T
  • 第五代CAR-T
• 新興的CAR-T技術
  • 體內CAR-T細胞療法
  • 現成的（同種異體）CAR-T細胞
  • 裝甲CAR-T
  • 基於邏輯閘的CAR-T細胞

第3章：CAR-T療法發展中的關鍵事件（1989-2026年）

• 塑造 CAR-T 療法革命的 15 個里程碑

第4章：CAR-T細胞療法的規模化生產

• 可擴展模型
• 目前正在使用的CAR-T細胞製造平台
• 自體CAR-T細胞療法的生產成本
• 同種異體CAR-T細胞療法的生產成本

第5章：CAR-T專利現狀

• 與 CAR-T 療法專利申請和獲得專利相關的費用。
• 2000 年 CAR-T 細胞療法專利申請數量
• 按司法管轄區分類的CAR-T相關專利申請分佈情況
• 與CAR-T細胞療法相關的專利申請量排名前20的公司
• 與CAR-T細胞療法相關的20位頂尖專利發明人
• CAR-T細胞療法專利擁有者量排名前20名的公司
• 與CAR-T細胞療法相關的專利申請的法律地位
• 與CAR-T細胞療法相關的前20項專利

第6章：CAR-T研究的演變現狀

• CAR-T研究論文的穩定發展
• PubMed.gov 上的一篇文章表明，異體 CAR-T 細胞療法將取代自體 CAR-T 細胞療法。
• CAR-T療法在固態腫瘤研究論文中取得突破性進展
• 一篇發表在PubMed上的關於CAR-T細胞療法革命的論文
• CAR-T療法在難治性自體免疫疾病緩解的下一個潛在應用

第7章：CAR-T細胞療法臨床試驗的擴展模式

• CAR-T細胞療法臨床試驗的最新趨勢
• 推進單一 CAR-T 細胞療法候選藥物研發的臨床試驗費用。
• 以CAR世代類型分類的CAR-T臨床試驗百分比
• 以共刺激域分類的 CAR-T 臨床試驗百分比
• 以標靶疾病分類的 CAR-T 臨床試驗百分比
• 以申辦單位類型分類的 CAR-T 臨床試驗
• CAR-T細胞療法臨床試驗中排名前五的醫院/臨床中心：市場佔有率
• CAR-T臨床試驗中排名前7位公司的市佔率
• 在排名前 7 的學術機構進行的 CAR-T 細胞臨床試驗的百分比。
• CAR-T臨床試驗目前處於研究階段。
• CAR-T細胞療法臨床試驗的資助者

第8章：CAR-T資金籌措現狀

• CAR-T領域的創業投資（2024-2026年）
• CAR-T 合作協議，2023 年 7 月
• CAR-T療法領域的併購
• 近年來，CAR-T細胞相關企業透過IPO募集的資金

第9章 全球核准的CAR-T細胞療法

• Kymriah（Tisagenrecrucel）
• Yescarta（Axiscabutagen，Shiroloylell）
• Tecartus（brexkabutagen autoleucel）
• Breyanzi（lysocabactene 馬來醯基纖維素）
• Abekuma（Idekabutagen/Vicrucel）
• Carvykti（Siltacaptagen Autoleucel）
• Aukazil（Obekabutagen autoleucel）
• Cartiva（relmacabutagen/autoleucel）
• Yikaida（軸舟/Shiroloycell）
• Zevor-cel（Zevorcabtagene Autoleucel）
• Yorwyda（Inathiobutagen autoleucel）
• Fukaso（equecabutagen autoleucel）
• Satricell（Satricabutagen/Autoleucel）
• Qartemi (Varnimkabutagenautoleucel)
• NexCAR19（Talikabutagen-Autoleucel）
• RIMQARTO(R)（Ambarcabutagen autoleucel）

第10章：2026年至2036年間最受期待的CAR-T療法獲批

• 以 Yescarta 為 CAR-T 細胞療法的前沿
• Breyanzi 處於 CAR-T 細胞療法的前沿。
• KYV-101 用於治療自體免疫疾病
• 雙標靶標準（CD19/CD20 CAR-T細胞）
• ALLO-501A/Cema-cel（同種異體「現成」）
• CTX112 新一代 CRISPR 編輯的 CAR-T 細胞
• JV-394 CAR-T 細胞（CD7/CD5/CD94 標靶）
• KIR-CAR-T細胞療法治療固態腫瘤
• FT819 iPSC衍生細胞療法
• 體內CAR-T細胞療法（一種無需實驗室的替代療法）
• CAR-T細胞療法標靶治療纖維化和衰老
• UCARTFAP
• FAP標靶體內mRNA-LNP

第11章：CAR-T療法的應用、研發與治療成本

• 在美國的使用情況
• 歐洲的使用情況
• 亞太地區的應用
• CAR-T細胞療法的醫療旅遊
• CAR-T細胞療法的生產成本
• CAR-T治療費用的區域差異

第12章 CAR-T細胞療法治療的疾病

• 血癌
• 自體免疫疾病
• 固態腫瘤
• 感染疾病和老年相關疾病
• CAR-T細胞療法在臨床上優於非CAR-T療法的方面

第13章 市場分析

• 全球CAR-T細胞療法產品市場
• 全球CAR-T細胞療法市場規模預測（2025-2035年）
• 全球 CAR-T 市場依適應症分類

第14章 CAR-T公司的分類

• 主要 CAR-T 公司依世代和訊號傳導方式分類
• 下一代CAR-T療法
• 提供 CAR-T 細胞療法的公司（依細胞來源分類：自體細胞與異體細胞）
• 以基因編輯/修飾技術列出的CAR-T細胞療法公司名單
• 以標靶技術和邏輯閘技術對CAR-T細胞療法公司進行分類
• 依適應症列出的 CAR-T 公司名單
• CAR-T細胞生產公司（依生產模式）
• 與相關企業的股權比例
• 按世代分類的CAR-T細胞療法公司的市場佔有率

第15章：公司簡介

• 4immune Therapeutics
• A2 Biotherapeutics, Inc.
• AAX Biotech AB
• AbbVie
• AbClon
• AbelZeta Pharma
• Adicet Bio
• Alaya.bio
• Aleta Biotherapeutics
• Allogene Therapeutics
• Allogenica
• AlloTera Therapeutics
• Alpha Biopharma
• Angeles Therapeutics
• Anixa Biosciences
• Antion Biosciences SA
• Arbele Limited
• Arcellx, Inc.
• ArsenalBio
• A-SEEDS Co., Ltd.
• AstraZeneca
• Atara Biotherapeutics
• Autolus Therapeutics
• AvenCell Therapeutics, Inc
• Beam Therapeutics
• BeiCell Therapeutics
• Bio4t2
• BioNTech SE
• BrainChild Bio
• Bristol Myers Squibb
• BioAgilytix
• BioOra
• Biosceptre International Limited
• Cabaletta Bio
• Capstan Therapeutics
• Caravan Biologix
• CARBio Therapeutics
• Caribou Biosciences
• Carina Biotech
• Caring Cross
• Caris Life Sciences
• CARsgen Therapeutics
• CARTemis Therapeutics GmbH
• Caris Life Sciences
• Cell-Easy
• Cellectis
• Cellepus Therapeutics
• Cellergy Pharma, Inc.
• Cellinfinity Bio
• Cellipont Bioservices
• Cell Therapies Pty Ltd
• Celluris
• Celularity Inc.
• Celyad Oncology SA
• Century Therapeutics
• Chimera Bioengineering
• Chimeric Therapeutics
• Circio Holding ASA
• Circio Holding ASA
• CREATE Medicines
• CrisprBits
• CRISPR Therapeutics AG
• Crown Bioscience
• Curocell
• Currus Biologics Pty Ltd
• Cyteph Pty Ltd
• Cytoart, Inc.
• Dispatch Bio
• Dynamic Cell Therapies, Inc
• EdiGene
• EdiGene
• Elicera Therapeutics AB
• Eli Lilly
• Elpis Biopharmaceuticals
• Epigenic Therapeutics
• EsoBiotec
• Essen BioTech
• Eureka Therapeutics
• EVA Pharma
• EXUMA Biotech
• FastBack Bio
• Fate Therapeutics
• Fosun Pharma
• Galapagos NV
• Gencyte Therapeutics
• Genentech Inc.
• Gilead Sciences
• Gennova Biopharmaceuticals
• GlycoMantra
• GoCART Therapeutics
• Gracell Biotechnologies
• Guangzhou Biogene Biotech Co., Ltd
• Gyala Therapeutics
• IASO Biotherapeutics
• iCell Gene Therapeutics, LLC
• Immuneel Therapeutics
• ImmunoACT
• Immunofoco
• Immunopharm Technology Co., Ltd
• Inceptor Bio
• Innovative Cellular Therapeutics
• Intellia Therapeutics
• Invectys, Inc.
• iO BiO Sciences
• Janssen Pharmaceuticals
• Jiangsu Pacific Meinuoke Biopharmaceuticals Co., Ltd
• JW Therapeutics
• Kelonia Therapeutics
• Kelonia Therapeutics
• Kiragen Bio
• Kite Pharma
• Kytopen Corp
• Kyverna Therapeutics
• Legend Biotech Corporation
• Leman Biotech Co., Ltd
• Leucid Bio
• Liminatus Pharma
• Link Cell Therapies
• Luminary Therapeutics
• Lyell Immunopharma
• March Biosciences, Inc
• MaxCyte, Inc
• MedTherapy Biotech
• Miltenyi Biomedicine GmbH
• Minerva Biotechnologies
• Mustang Bio
• Nexcella, Inc
• Noile-Immune Biotech Inc
• Novartis International AG
• Novatim Immune Therapeutics
• OneChain Immunotherapeutics
• OncoC4, Inc
• Optieum Biotechnologies
• OriCell Therapeutics
• Orna Therapeutics
• Outpace Bio
• PeproMene Bio
• Poseida Therapeutics
• Precigen
• Precision Biosciences
• Prescient Therapeutics Ltd
• Priothera, Ltd
• ProMab Biotechnologies, Inc
• PromiCell
• Regeneron
• Roche Group
• Sana Biotechnology
• Senti Bio
• Shenzhen MagicRNA Biotechnology Co., Ltd
• Shenzhen Pregene Biopharma Co., Ltd
• Simnova Biotherapeutics
• Strand Therapeutics
• Synlico, Inc.
• TC Biopharm
• T-CURX GmbH
• Terumo BCT
• TG Therapeutics
• Thermo Fisher Scientific
• Tikva Allocell Pte Ltd
• TriArm Therapeutics
• T-Maximum Pharmaceutical
• Ucello Therapeutics
• Umoja Biopharma
• Vector BioMed, Inc
• Verismo Therapeutics
• Vittoria Biotherapeutics
• Waypoint Bio
• Wugen, Inc
• Xcell Biosciences
• Xenetic Biosciences, Inc.
• Xyphos Biosciences
• YolTech Therapeutics

CAR-T REPORT EXECUTIVE SUMMARY

CAR-T cell therapy is a groundbreaking advancement in cancer treatment, offering remarkable promise for patients. This form of immunotherapy utilizes the power of the body's own immune cells, modifying them in a lab to enhance their ability to recognize and destroy cancer cells. Once infused back into the patient, these engineered cells multiply and persist in the body as "living drugs," continually working to fight the disease.

Global Regulatory Approvals

Since 2017, 16 CAR-T cell therapies have reached commercialization across multiple healthcare markets, up from 13 just a year ago. Seven therapies have been approved by the U.S. FDA. These therapies include:

• 1. Kymriah (tisagenlecleucel)
• 2. Yescarta (axicabtagene ciloleucel)
• 3. Tecartus (brexucabtagene autoleucel)
• 4. Breyanzi (lisocabtagene maraleucel)
• 5. Abecma (idecabtagene vicleucel)
• 6. Carvykti (ciltacabtagene autoleucel)
• 7. Aucatzyl (obecabtagene autoleucel)

Beyond the U.S., six CAR-T therapies (Carteyva, Yikaida, Zevor-cel, Yorwida, Fucaso, and Satri-cel) have been approved by China's National Medical Products Administration (NMPA), including Satri-cel, the world's first regulatory approval of a CAR-T cell therapy for a solid tumor.

Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India's Central Drugs Standard Control Organisation (CDSCO). Rounding out the global landscape, South Korea's Ministry of Food and Drug Safety (MFDS) approved the country's first domestically developed CAR-T therapy, RIMQARTO, marking the entry of a new regulatory market into the commercial CAR-T landscape.

CAR-T Market Expansion and Industry Growth

These regulatory approvals mark a major milestone, solidifying the CAR-T market as a dominant force in biotech. Mergers and acquisitions have only accelerated, demonstrating strong and growing investor confidence. The industry's formative deals, including Celgene's acquisition of Juno Therapeutics for $9 billion, Bristol-Myers Squibb's subsequent acquisition of Celgene for $74 billion, Gilead's acquisition of Kite Pharma for $11.9 billion, and Astellas Pharma's purchase of Xyphos Biosciences for $665 million, established CAR-T as a must-own capability for large pharma.

That appetite hasn't slowed. Since 2024 alone, the industry has recorded over $8 billion in additional licensing deals and acquisitions, including AbbVie's acquisition of Capstan Therapeutics, Roche's acquisition of Poseida Therapeutics, and Bristol Myers Squibb's acquisition of Orbital Therapeutics, as pharmaceutical giants race to secure next-generation platform technologies. These transactions highlight the increasing commitment from major pharmaceutical companies to invest in CAR-T technologies and shape the future of cancer treatment.

As CAR-T therapy continues to evolve, the industry faces key challenges, including improving gene-transfer efficiency and mitigating toxicity risks. Researchers are actively exploring CRISPR and electroporation technologies to enhance T-cell modification, while others develop "on-off" switches to regulate CAR-T activity.

One of the biggest hurdles has long been the treatment of solid tumors, as clinical trials have shown lower response rates compared to blood cancers. This is changing: nearly 290 registered clinical trials are now targeting solid tumors, and China's approval of Satri-cel proves the barrier is no longer insurmountable. A major focus remains on identifying solid tumor-specific antigens to further improve efficacy in these cancers.

Beyond oncology, the industry is making an aggressive push into autoimmune disease. Over 250 active clinical trials are now exploring CAR-T's potential to treat conditions like systemic lupus erythematosus (SLE), systemic sclerosis, and multiple sclerosis, with early data showing drug-free remissions in some patients.

Currently, the marketed CAR-T therapy landscape and the large majority of ongoing clinical trials rely on autologous (patient-derived) cells. However, the next breakthrough lies in allogeneic CAR-T therapies, which are off-the-shelf solutions that could streamline manufacturing, reduce costs, and expand patient accessibility.

Global CAR-T Cell Therapy Market

The CAR-T cell therapy market has grown from early experimental treatments to a multi-billion-dollar industry with global reach. Early successes in blood cancers have paved the way for broader applications, with companies ranging from startups to biotech giants working to expand the field. As innovation continues, the future of CAR-T therapy holds immense potential to revolutionize cancer treatment worldwide.

This report provides the following insights:

• A brief history of CAR-T therapy, highlighting its evolution from 1989 to the present, its transformative potential, and the accelerating activities within the CAR-T sector.
• An examination of the manufacturing process and the costs associated with developing autologous and allogeneic CAR-T cell therapies.
• An overview of cancer biomarkers or antigens targeted by CAR-T cells.
• A detailed analysis of the global CAR-T patent landscape, including leading sponsors, inventors, and regions.
• An in-depth look at the rates, types, and trends for clinical trials involving CAR-T cells, including its rapidly emerging role in autoimmune disease.
• A review of the rates and types of CAR-T cell therapy scientific publications.
• An overview of NIH grants awarded to support CAR-T cell therapy research.
• A review of industry dealmaking and strategic partnerships within the CAR-T sector.
• Descriptions of all 16 globally approved CAR-T therapies, including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Aucatzyl, Carteyva, Yikaida, Zevor-cel, Yorwida, Fucaso, Satri-cel, NexCAR19, Qartemi, and RIMQARTO.
• A review of reimbursement policies for CAR-T therapies in the U.S. and outcome-based reimbursement policies in Europe.
• A global market analysis for CAR-T cell therapies by Geography, Product, and Indication.
• Profiles of over 170 leading CAR-T cell therapy market competitors, including their novel products, emerging candidates, and proprietary technology platforms.
• And so much more.

Key Questions Answered in This Report:

• What are the features of the FDA-approved CAR-T therapies that are currently available, who is manufacturing them, and who is commercializing them?
• What future developments are expected within the CAR-T sector?
• Which new CAR-T products are anticipated to enter the market soon?
• How many automated manufacturing systems are available for CAR-T production?
• Which antigens are most commonly targeted in liquid and solid cancers?
• What is the number of CAR-T-related patent publications and granted patents from 2012 to present?
• Which countries hold the most CAR-T patents?
• Which companies have filed the most CAR-T patents?
• Who are the top CAR-T patent inventors?
• How many CAR-T-related clinical trials have been registered from 2003 to the present?
• Which biomarker antigens dominate the CAR-T clinical trial landscape?
• How many CAR-T deals were signed in the past two years and who entered into them?
• What is the current market size for globally approved CAR-T therapies?
• What promising CAR-T candidates are expected to reach commercialization soon?
• How are CAR-T therapies reimbursed in the U.S. and Europe?
• What is the market size for CAR-T therapies by geography, product, and indication?
• Which major companies are developing CAR-T cell therapies?
• And so much more.

This global strategic report will position you to:

• Capitalize on rapidly emerging trends
• Optimize decision-making
• Reduce company risk
• Approach partners/investors for collaboration or funding
• Implement an informed and advantageous business strategy through 2035 and beyond

With the competitive nature of this global market, you don't have the time to do the research. Claim this report to become immediately informed, without missing critical opportunities.

Companies and Organizations Mentioned

Novartis, Gilead Sciences, Kite Pharma, Bristol Myers Squibb, 2seventy bio, Legend Biotech, Janssen Pharmaceuticals, Autolus Therapeutics, JW Therapeutics, Fosun Pharma, CARsgen Therapeutics, IASO Biotherapeutics, Immuneel Therapeutics, ImmunoACT, Curocell, AbbVie, AstraZeneca, Roche Group, Eli Lilly, Regeneron, Genentech, BioNTech, Sana Biotechnology, Arcellx, Allogene Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Precision Biosciences, Century Therapeutics, Fate Therapeutics, Beam Therapeutics, Editas Medicine, Cartesian Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Capstan Therapeutics, Orbital Therapeutics, Umoja Biopharma, Lyell Immunopharma, Mustang Bio, Vor Biopharma, Gracell Biotechnologies, Poseida Therapeutics, Adicet Bio, Atara Biotherapeutics, Cellectis, Celyad Oncology, Wugen, Strand Therapeutics, Waypoint Bio, Kelonia Therapeutics, ArsenalBio, Anixa Biosciences, Xyphos Biosciences, Antion Biosciences, Miltenyi Biomedicine, MaxCyte, Thermo Fisher Scientific, Terumo BCT, and 112 more.

About the Publisher

Founded in 2006, the publisher is the world’s first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, it has been tracking this market for 20+ years, developing proprietary datasets, extracting trend data, and conducting industry interviews to which AI doesn't have access.

To date, the publisher’s research has been cited by the Wall Street Journal, AABB, and Vogue Magazine, as well as quoted by Tony Robbins in his best-selling book, LifeForce. Today, the publisher operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, it is your global leader in stem cell and cell therapy industry data.

1. REPORT OVERVIEW

• 1.1 Statement of the Report
• 1.2 Executive Summary
• 1.3 Introduction

2. CAR-T CELL THERAPY & CAR-T TECHNOLOGIES

• 2.1 Structure of a CAR-T Cell
• 2.2 Engineering of T Cells into CAR-T Cells
• 2.3 The Five Generations of CAR-Ts
  • 2.3.1 1st Generation CAR-T
  • 2.3.2 2nd Generation CAR-T
  • 2.3.3 3rd Generation CAR-T
  • 2.3.4 4th Generation CAR-T
  • 2.3.5 5th Generation CAR-T
• 2.4 Emerging CAR-T Technologies
  • 2.4.1 In Vivo CAR-T Cell Therapy
  • 2.4.2 Off-the-Shelf (Allogeneic) CAR-T Cells
  • 2.4.3 Armored CAR-Ts
  • 2.4.4 Logic-Gated CAR-T Cells

3. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2026

• 3.1 Fifteen Milestones that Shaped the CAR-T Revolution
  • 3.1.1 First CAR Prototype (1993)
  • 3.1.2 Second-Generation CAR Invention (1998)
  • 3.1.3 CD19 Target Defined (2002)
  • 3.1.4 First Adult CLL Remission (2010)
  • 3.1.5 Emily Whitehead Breakthrough (2012)
  • 3.1.6 First FDA Breakthrough Designation (2014)
  • 3.1.7 Historical First FDA Approval (2017)
  • 3.1.8 Solidifying Adult Lymphoma Market (2017)
  • 3.1.9 First Mantle Cell Lymphoma Approval (2020)
  • 3.1.10 Entering Multiple Myeloma (2021)
  • 3.1.11 Expansion into Autoimmune Diseases (2022)
  • 3.1.12 Solid Tumor Breakthroughs (2023)
  • 3.1.13 Allogeneic "Off-the-Shelf" Validation (2024)
  • 3.1.14 Point-of-Care (Hospital Bedside) Manufacturing (2025)
  • 3.1.15 In Vivo mRNA Platforms (2026)

4. SCALABLE MANUFACTURING OF CAR-T CELL THERAPIES

• 4.1 Scalability Models
  • 4.1.1 Scale-Out Model (Autologous)
    • 4.1.1.1 Core Mechanics of the Scale-Out Model
    • 4.1.1.2 Centralized Scale-Out Model
    • 4.1.1.3 Decentralized Scale-Out Model
    • 4.1.1.4 The End-to-End Scale-Out Workflow
  • 4.1.2 Scale-Up Model (Allogeneic)
    • 4.1.2.1 Core Workflow of Allogeneic Scale-Up
• 4.2 Currently Used CAR-T Manufacturing Platforms
  • 4.2.1 All-in-One Integrated Instruments
  • 4.2.2 The Market Leader in All-in-One Integrated Platforms
    • 4.2.2.1 CliniMACS’ Closest Competitor
  • 4.2.3 Modular & Specialized Expansion Bioreactors
    • 4.2.3.1 Largest-Selling Modular & Specialized Expansion Bioreactors
      • 4.2.3.1.1 The Static Leader: Wilson Wolf G-Rex Platform
      • 4.2.3.1.2 The Dynamic Leader: Cytiva Xuri W25 Cell Expansion System
• 4.3 Cost of Manufacturing Autologous CAR-T Cell Therapies
  • 4.3.1 Emerging Models Altering the Cost Landscape
• 4.4 Cost of Manufacturing Allogeneic CAR-T Cell Therapies

5. CAR-T PATENT LANDSCAPE

• 5.1 Cost of Filing and Securing a CAR-T Therapy Patent
  • 5.1.1 Licensing Cost of CAR-T Cell Therapy Patents
    • 5.1.1.1 Top 10 CAR-T Cell Therapy Licensing Deals
• 5.2 Number of CAR-T Cell Therapy Patent Filings, 2000 to
  • 5.2.1 Patent Filings for Autologous & Allogeneic CAR-T Therapies Compared
  • 5.2.2 Patent Filings by CAR-T Generation Type
  • 5.2.3 Patent Filings for Blood Cancers & Solid Tumors Compared, 2015-2025
  • 5.2.4 CAR-T Patent Filings for Autoimmune Diseases
  • 5.2.5 Patent Filings for In Vivo CAR-T Cell Therapies
• 5.3 Distribution of Filed CAR-T Patents by Jurisdiction
  • 5.3.1 Top 20 CAR-T Cell Therapy Jurisdictions
• 5.4 Top 20 CAR-T Cell Therapy Patent Applicants
• 5.5 Top 20 CAR-T Cell Therapy Patent Inventors
• 5.6 Top 20 CAR-T Cell Therapy Patent Owners
• 5.7 Legal Status of CAR-T Cell Therapy Filed Patents
  • 5.7.1 Macro Global Patent Portfolio Distribution
• 5.8 Top 20 Granted CAR-T Cell Therapy Patents

6. EVOLVING LANDSCAPES IN CAR-T RESEARCH

• 6.1 The Bedrock Ascent of CAR-T Research Publications
• 6.2 The Allogeneic Ascent over Autologous CAR-T PubMed.gov Publications
• 6.3 The Solid Tumor Breakthrough in CAR-T Research Publications
• 6.4 PubMed Papers on CAR-T In Situ Revolution
• 6.5 CAR-T’s Next Frontier in Refractory Autoimmune Remission
  • 6.5.1 Mechanism of Action & Immune Reset
  • 6.5.2 Top Clinical Indications & Successes

7. THE EXPANDING MAP OF CAR-T CLINICAL TRIALS

• 7.1 Recent Trends in CAR-T Cell Therapy Clinical Trials
• 7.2 Clinical Trial Cost to Advance a Single CAR-T Cell Therapy Candidate
• 7.3 Percent Share of CAR-T Clinical Trials by CAR Generation Type
• 7.4 Percent Share of CAR-T Clinical Trials by Co-stimulatory Domains
• 7.5 Percent Share of CAR-T Clinical Trials by Target Disease
• 7.6 CAR-T Clinical Trials by Sponsor Type
• 7.7 Percent Share of Top 5 Hospitals & Clinical Centers in CAR-T Clinical Trials
• 7.8 Percent Share of Top 7 Companies in CAR-T Clinical Trials
• 7.9 Percent Share of CAR-T Clinical Trials by Top 7 Academic Institutions
• 7.10 CAR-T Clinical Trials’ Study Phases
• 7.11 Funders of CAR-T Clinical Trials

8. CAR-T FUNDING LANDSCAPE

• 8.1 Venture Capital Funding in CAR-T Sector, 2024-2026
  • 8.1.1 Legend Biotech
  • 8.1.2 Waypoint Bio
  • 8.1.3 CREATE Medicines, Inc.
  • 8.1.4 Orca Bio
  • 8.1.5 Orum Therapeutics
  • 8.1.6 Syneron Bio
  • 8.1.7 Link Cell Therapies
  • 8.1.8 MagicRNA Biotech
  • 8.1.9 Wugen
  • 8.1.10 Innovacell
  • 8.1.11 Anocca
  • 8.1.12 Strand Therapeutics
  • 8.1.13 ArsenalBio
  • 8.1.14 Capstan Therapeutics
  • 8.1.15 YolTech Therapeutics
• 8.2 CAR-T Collaboration Deals, 2023- July,
  • 8.2.1 Johnson & Johnson/Sail Biomedicines
  • 8.2.2 Circio Holding ASA & Tcelltech GmbH
  • 8.2.3 Helix Cell Therapeutics & Biocell Innovations
  • 8.2.4 Applied Cells, Inc. & Immuneel Therapeutics
  • 8.2.5 Dispatch Bio & CARsgen Therapeutics
  • 8.2.6 Cellares & University of Wisconsin School of Medicine
  • 8.2.7 A-SEEDS, Co., Ltd. & Cell Therapies Pty Ltd.
  • 8.2.8 Kytopen Corporation & Excellos, Inc.
  • 8.2.9 Kelonia Therapeutics & Janssen Biotech, Inc.
  • 8.2.10 Gilead's Kite Pharma & Pregene Biopharma
  • 8.2.11 Gilead's Kite Pharma & Interius BioTherapeutics
  • 8.2.12 Proton Advanced Solutions & EVA Pharma
  • 8.2.13 Vector BioMed & Muni Seva Ashram
  • 8.2.14 Gilead's Kite Pharma & Arcellx
  • 8.2.15 Caring Cross & ImmunoACT
  • 8.2.16 Bristol Myers Squibb & Cellares
  • 8.2.17 Gilead Sciences (Kite) & Arcellx
  • 8.2.18 ImmunoACT, IIT Bombay, & Tata Memorial Centre
  • 8.2.19 Janssen Biotech & Cellular Biomedicine Group
  • 8.2.20 Johnson & Johnson and Novartis
• 8.3 Merger & Acquisition Deals in CAR-T Therapy Sector
  • 8.3.1 Merger & Acquisition in
    • 8.3.1.1 Johnson & Johnson Acquires Sail Biomedicines
    • 8.3.1.2 Liminatus Pharma Acquires InnocsAI LLC
    • 8.3.1.3 Gilead Sciences, Inc. Acquires Arcellx, Inc.
    • 8.3.1.4 Eli Lilly Acquires Kelonia Therapeutics
    • 8.3.1.5 Eli Lilly Acquires Orna Therapeutics
    • 8.3.1.6 Bristol Myers Squibb Acquires Orbital Therapeutics
    • 8.3.1.7 AbbVie Acquires Capstan Therapeutics
    • 8.3.1.8 AstraZeneca Acquires Esco Biotec
    • 8.3.1.9 Roche Acquires Poseida Therapeutics
    • 8.3.1.10 AstraZeneca Acquires Gracell Biotechnologies
• 8.4 IPO Funding Raised by CAR-T Companies in Recent Years
  • 8.4.1 Legend Biotech
  • 8.4.2 Cabaletta Bio
  • 8.4.3 Editas Medicine
  • 8.4.4 Allogene Therapeutics
  • 8.4.5 Artiva Biotherapeutics
  • 8.4.6 Autolus Therapeutics
  • 8.4.7 Kyverna Therapeutics

9. GLOBALLY APPROVED CAR-T CELL THERAPIES

• 9.1 Kymriah (tisagenlecleucel)
  • 9.1.1 Product Description
  • 9.1.2 Foundational Technology
    • 9.1.2.1 Patent Protection
  • 9.1.3 Indications Approved for Kymriah
    • 9.1.3.1 Dates of Approvals for Different Indications
  • 9.1.4 Marketing Status
  • 9.1.5 Development Timeline for Kymriah
  • 9.1.6 Manufacturing of Kymriah
    • 9.1.6.1 Manufacturing Locations
  • 9.1.7 Certified Kymriah Treatment Centers
  • 9.1.8 Cost of Treatment
    • 9.1.8.1 Estimated Out-of-Pocket Costs & Regional Variations
  • 9.1.9 Competing Therapies with Kymriah
  • 9.1.10 Revenue Generation by Kymriah
• 9.2 Yescarta (axicabtagene ciloleucel)
  • 9.2.1 Product Description
  • 9.2.2 Foundational Technology
    • 9.2.2.1 Patent Protection
  • 9.2.3 Indications Approved for Yescarta
  • 9.2.4 Approval of Yescarta in Different Countries
  • 9.2.5 Development Timeline of Yescarta
  • 9.2.6 Manufacturing Process
    • 9.2.6.1 Manufacturing Locations
  • 9.2.7 Treatment Centers
  • 9.2.8 Treatment Cost
  • 9.2.9 Competing Therapies
  • 9.2.10 Revenue Generation
• 9.3 Tecartus (brexucabtagene autoleucel)
  • 9.3.1 Product Description
  • 9.3.2 Foundational Technology & Patent Protection
  • 9.3.3 Indications Approved for Tecartus
  • 9.3.4 Dates of Approvals
  • 9.3.5 Development Timeline
  • 9.3.6 Manufacturing Process
    • 9.3.6.1 Manufacturing Location
  • 9.3.7 Cost of Treatment
  • 9.3.8 Competing Therapies
  • 9.3.9 Revenue Generation
• 9.4 Breyanzi (lisocabtagene maraleucel)
  • 9.4.1 Product Description
  • 9.4.2 Foundational Technology
    • 9.4.2.1 Patent Protection
  • 9.4.3 Approved Indications for Breyanzi
  • 9.4.4 Dates of Approval by Country/Region
  • 9.4.5 Development Timeline
  • 9.4.6 Manufacturing Process
    • 9.4.6.1 Manufacturing Locations
  • 9.4.7 Authorized Treatment Centers
    • 9.4.7.1 Cost of Treatment
  • 9.4.8 Competing Therapies
  • 9.4.9 Revenue Generation
• 9.5 Abecma (idecabtagene vicleucel)
  • 9.5.1 Product Description
  • 9.5.2 Foundational Technology
  • 9.5.3 Patent Protection
  • 9.5.4 Approved Indications
  • 9.5.5 Dates of Approval
  • 9.5.6 Development Timeline
  • 9.5.7 Manufacturing Process
    • 9.5.7.1 Manufacturing Location
  • 9.5.8 Certified Treatment Centers
  • 9.5.9 Treatment Cost
  • 9.5.10 Competing Therapies
  • 9.5.11 Revenue Generation
• 9.6 Carvykti (ciltacabtagene autoleucel)
  • 9.6.1 Product Description
  • 9.6.2 Foundational Technology
    • 9.6.2.1 Patent Protection
  • 9.6.3 Approved Indications
  • 9.6.4 Dates of Approval
  • 9.6.5 Development Timeline of Carvykti
    • 9.6.6.1 Manufacturing Locations
  • 9.6.7 Certified Treatment Centers
  • 9.6.8 Cost of Treatment
  • 9.6.9 Competing Therapies
  • 9.6.10 Revenue Generation
• 9.7 Aucatzyl (obecabtagene autoleucel)
  • 9.7.1 Product Description
  • 9.7.2 Foundational Technology
    • 9.7.2.1 Patent Protection
  • 9.7.3 Approved Indications
  • 9.7.3 Dates of Approval
  • 9.7.4 Marketing Status
  • 9.7.5 Development Timeline
  • 9.7.6 Manufacturing
  • 9.7.7 Manufacturing Location
  • 9.7.8 Cost of Treatment
  • 9.7.9 Other Competing Therapies
  • 9.7.10 Revenue Generation
• 9.8 Carteyva (relmacabtagene autoleucel)
  • 9.8.1 Product Description
  • 9.8.2 Foundational Technology
  • 9.8.3 Approved Indications
  • 9.8.4 Dates of Approval
  • 9.8.5 Marketing Status
  • 9.8.6 Development Timeline
  • 9.8.7 Manufacture
  • 9.8.8 Manufacturing Location
  • 9.8.9 Cost of Treatment
  • 9.8.10 Competing Therapies
  • 9.8.11 Revenue Generation
• 9.9 Yikaida (axicabtagene ciloleucel)
  • 9.9.1 Product Description
  • 9.9.2 Foundational Technology
    • 9.9.2.1 Patent Protection
  • 9.9.3 Approved Indications
  • 9.9.4 Dates of Approval
  • 9.9.5 Marketing Status
  • 9.9.6 Development Timeline
  • 9.9.7 Manufacturing Process
    • 9.9.7.1 Manufacturing Location
  • 9.9.8 Certified Treatment Centers
  • 9.9.9 Cost of Treatment
  • 9.9.10 Approved Competing Therapies
  • 9.9.11 Revenue Generation
• 9.10 Zevor-cel (Zevorcabtagene Autoleucel)
  • 9.10.1 Product Description
  • 9.10.2 Foundational Technology
  • 9.10.3 Approved Indications
  • 9.10.4 Approval Date
  • 9.10.5 Development Timeline
  • 9.10.6 Manufacturing
    • 9.10.6.1 Manufacturing Locations
  • 9.10.7 Certified Treatment Centers
  • 9.10.8 Cost of Treatment
  • 9.10.9 Approved Competing Therapies
  • 9.10.10 Revenue Generation
• 9.11 Yorwida (inaticabtagene autoleucel)
  • 9.11.1 Product Description
  • 9.11.2 Foundational Technology
  • 9.11.3 Approved Indications
  • 9.11.4 Dates of Approval
  • 9.11.5 Marketing Status
  • 9.11.6 Development Timeline
  • 9.11.7 Manufacturing
    • 9.11.7.1 Manufacturing Location
  • 9.11.8 Authorized Treatment Centers
  • 9.11.9 Cost of Treatment
  • 9.11.10 Approved Competing Therapies
• 9.12 Fucaso (equecabtagene autoleucel)
  • 9.12.1 Product Description
  • 9.12.2 Foundational Technology
    • 9.12.2.1 Patent Protection
  • 9.12.3 Approved Indications
  • 9.12.4 Dates of Approval
  • 9.12.5 Marketing Status
  • 9.12.6 Development Timeline
  • 9.12.7 Manufacturing
    • 9.12.7.1 Manufacturing Locations
  • 9.12.8 Cost of Treatment
  • 9.12.9 Competing Approved Therapies
• 9.13 Satri-cel (Satricabtagene Autoleucel)
  • 9.13.1 Product Description
  • 9.13.2 Approved Indications
  • 9.13.3 Date of Approval
  • 9.13.4 Marketing Status
  • 9.13.5 Development Timeline
  • 9.13.6 Manufacturing Process
    • 9.13.6.1 Manufacturing Location
  • 9.13.7 Certified Treatment Centers
  • 9.13.8 Cost of Treatment
  • 9.13.9 Approved Competing Therapies
• 9.14 Qartemi (varnimcabtagene autoleucel)
  • 9.14.1 Product Description
  • 9.14.2 Foundational Technology
  • 9.14.3 Approved Indications
  • 9.14.4 Dates of Approval
  • 9.14.5 Marketing Status
  • 9.14.6 Development Timeline
  • 9.14.7 Manufacturing
    • 9.14.7.1 Manufacturing Location
  • 9.14.8 Certified Treatment Centers
  • 9.14.9 Cost of Treatment
  • 9.14.10 Approved CAR-T & Non-CAR-T Competing Therapies
  • 9.14.11 Revenue Generation
• 9.15 NexCAR19 (talicabtagene autoleucel)
  • 9.15.1 Product Description
  • 9.15.2 Foundational Technology
  • 9.15.3 Approved Indications
  • 9.15.4 Date of Approval
  • 9.15.5 Marketing Status
  • 9.15.6 Development Timeline
  • 9.15.7 Manufacturing
    • 9.15.7.1 Manufacturing Location
  • 9.15.9 Certified Treatment Centers
• 9.16 RIMQARTO® (anbalcabtagene autoleucel)
  • 9.16.1 Product Description
  • 9.16.2 Foundational Technology
  • 9.16.3 Approved Indications
  • 9.16.4 Date of Approval
  • 9.16.5 Marketing Status
  • 9.16.6 Development Timeline
  • 9.16.7 Manufacturing
    • 9.16.7.1 Manufacturing Location

10. MOST ANTICIPATED CAR-T APPROVALS BETWEEN 2026 AND 2036

• 10.1 Yescarta as Frontline CAR-T Cell Therapy
• 10.2 Breyanzi as Frontline CAR-T Cell Therapy
• 10.3 KYV-101 for Autoimmune Diseases
• 10.4 Dual-Targeting Standard (CD19/CD20 CAR-Ts)
  • 10.4.1 Dual-Targeting JNJ-4496
  • 10.4.2 Dual-Targeting KITE-363
• 10.5 ALLO-501A/Cema-cel (Allogeneic "Off-the-Shelf")
• 10.6 CTX112 Next-Gen CRISPR-Edited CAR-T
• 10.7 JV-394 CAR-T Targeting CD7/CD5/CD94
• 10.8 KIR-CAR-T Cell Therapies for Solid Tumors
• 10.9 FT819 iPSC-Derived Cellular Therapy
  • 10.9.1 Key Engineering Modifications in FT819
  • 10.9.2 Clinical Milestones & Trial Updates for FT819
• 10.10 In Vivo CAR-T Therapeutics (The "No-Lab" Alternative)
  • 10.10.1 Cutting-Edge In Vivo CAR-T Candidates in Clinical Trials
    • 10.10.1.1 KLN-1010 (inMMyCAR Trial)
    • 10.10.1.2 INT2104
    • 10.10.1.3 ORN-252/Orna Therapeutics
• 10.11 CAR-Ts targeting Fibrosis and Senescence
• 10.12 UCARTFAP
• 10.13 FAP-Targeted In Vivo mRNA-LNP

11. CAR-T UTILIZATION, COST OF DEVELOPMENT AND TREATMENT

• 11.1 Utilization in the U.S.
• 11.2 Utilization in Europe
• 11.3 Utilization in Asia/Pacific
• 11.4 Medical Tourism in the Context of CAR-T Treatment
  • 11.4.1 Top Global Hubs for CAR-T Medical Tourism
    • 11.4.1.1 Value of CAR-T Treatment through Medical Tourism
    • 11.4.1.2 Hidden Costs and “Total Budget” Math for Travelers
  • 11.4.2 Two Prominent Destinations for International Patients
    • 11.4.2.1 Turkey
      • 11.4.2.1.1 Top Hospitals & Accreditations in Turkey
    • 11.4.2.2 India
      • 11.4.2.2.1 Patient Demographics by Region
      • 11.4.2.2.2 Key Indian Centers Accommodating Foreign Patients
• 11.5 Manufacturing Cost of CAR-T Cell Therapy
  • 11.5.1 Cost of Developing CAR-T Therapy from Discovery to Marketing Approval
  • 11.5.2 Cost of Developing CAR-T Therapy from Academics to Spinouts
• 11.6 Cost of CAR-T Treatments across Geographies
  • 11.6.1 Total Treatment Cost for CAR-T Cell Therapies in the United States
  • 11.6.2 Total CAR-T Treatment Cost in Europe
  • 11.6.3 Total CAR-T Treatment Cost in Japan
  • 11.6.4 Total CAR-T Treatment Cost in South Korea
  • 11.6.5 Total CAR-T Treatment Cost in Australia
  • 11.6.6 Total CAR-T Treatment Cost in China
  • 11.6.7 Total CAR-T Treatment Cost in India

12. DISEASES TREATED WITH CAR-T CELL THERAPIES

• 12.1 Blood Cancers
  • 12.1.1 Acute Lymphoblastic Leukemia (ALL)
  • 12.1.2 B-Cell Lymphomas
  • 12.1.3 Multiple Myeloma
• 12.2 Autoimmune diseases
  • 12.2.1 Systemic Lupus Erythematosus (SLE)
    • 12.2.1.1 CAR-T Development for SLE
  • 12.2.2 Multiple Sclerosis (MS)
  • 12.2.3 Pemphigus Vulgaris (PV)
    • 12.2.3.1 Development of CAR-T for PV
  • 12.2.4 Systemic Sclerosis (SSc)
    • 12.2.4.1 CAR-T Development for SSc
      • 12.2.4.1.1 Prominent CAR-T Clinical Trial Candidates for SSc
• 12.3 Solid Tumors
  • 12.3.1 Gastrointestinal & Abdominal Cancers
  • 12.3.2 Brain & Central Nervous System (CNS) Tumors
  • 12.3.3 Lung and Thoracic Cancers
  • 12.3.4 Pediatric and Musculoskeletal Cancers
• 12.4 Infectious and Senescence-Associated Diseases
  • 12.4.1 CAR-T Applications in Infectious Diseases
  • 12.4.2 CAR-T Applications in Senescence-Associated Diseases
• 12.5 The Clinical Superiority of CAR-T Cell Therapy over Non-CAR-T Therapies
  • 12.5.1 "Living Drug" Dynamics (Long-Term Vigilance)
  • 12.5.2 MHC-Independent Target Recognition
  • 12.5.3 Laser-Focused Specificity
  • 12.5.4 Single Infusion vs. Continuous Treatment Cycles

13. MARKET ANALYSIS

• 13.1 Global Market for CAR-T Cell Therapy Products
  • 13.1.1 Sales of FDA-Approved CAR-T Cell Therapy Products between 2017 and
  • 13.1.2 Sales History of CAR-T Cell Therapies Approved in China
  • 13.1.3 Sales History of Approved CAR-T Cell Therapies in India
  • 13.1.4 RIMQARTO: The South Korean Approved CAR-T
    • 13.1.4.1 The Reimbursement Gateway (The Ultimate Sales Driver)
    • 13.1.4.2 Pricing and Cost Competitiveness
    • 13.1.4.3 Clinical Edge Driving Market Capture
• 13.2 Estimated Global Market for CAR-T Cell Therapies, 2025-2035
  • 13.2.1 Global CAR-T Cell Therapy Market by Targeted Antigens, 2017-2025
  • 13.2.2 Estimated Global Market for CAR-T Therapies by Target Antigen, 2025-2035
• 13.3 Global CAR-T Market by Indication
  • 13.3.1 The Percent Share of CAR-T Market by Approved Indications
    • 13.3.1.1 Global CAR-T Market by Lymphoma Sub-Type
    • 13.3.1.2 CAR-T Market for Multiple Myeloma by Sub-Type
  • 13.3.2 CAR-T Market for Leukemia Indications
  • 13.3.3 CAR-T for Solid Tumor Indications

14. CATEGORIES OF CAR-T COMPANIES

• 14.1 Key CAR-T Companies by Generation and Signaling
• 14.2 Next-Generation CAR-Ts
  • 14.2.1 Comparison of Second Generation & Next-Generation CAR-Ts
• 14.3 CAR-T Companies by Cellular Source (Autologous vs. Allogeneic)
• 14.4 CAR-T Companies by Gene Editing/Modification Technology
• 14.5 CAR-T Companies by Targeting and Logic Gate Technology
• 14.6 CAR-T Companies by Indication Specialization
• 14.7 CAR-T Companies by Production model
• 14.8 Percent Shares of Autologous & Allogeneic CAR-T Companies
• 14.9 Percent Share of CAR-T Companies by Generation Types

15. COMPANY PROFILES

• 15.1 4immune Therapeutics
  • 15.1.1 CAL/CAR-T Cell Therapy Platform
• 15.2 A2 Biotherapeutics, Inc.
  • 15.2.1 Tmod™
  • 15.2.2 A2 Biotherapeutics’ RD Pipeline
• 15.3 AAX Biotech AB
  • 15.3.1 Seqitope®
  • 15.3.2 Opti-mAb®
• 15.4 AbbVie
  • 15.4.1 Key CAR-T Programs & Partnerships
• 15.5 AbClon
  • 15.5.1 NEST Platform
  • 15.5.2 zCAR-T Platform
  • 15.5.3 AbClon’s CAR-T Product Candidates
• 15.6 AbelZeta Pharma
  • 15.6.1 RMAT designation for C-CAR168
  • 15.6.2 Armored CAR-T Technology
  • 15.6.3 GPC3-Targeting CAR-T (C-CAR031)
• 15.7 Adicet Bio
  • 15.7.1 Leading Clinical Candidates
• 15.8 Alaya.bio
  • 15.8.1 Core Technology
  • 15.8.2 Partnerships & Milestones
• 15.9 Aleta Biotherapeutics
  • 15.9.1 CAR-T Engagers (CTEs)
• 15.10 Allogene Therapeutics
  • 15.10.1 AlloCAR T™ Platform
  • 15.10.2 Dagger™ Technology
  • 15.10.3 TurboCAR™ technology
  • 15.10.4 ALLO-647 (Lymphodepletion)
  • 15.10.5 Cloak™ Technology
• 15.11 Allogenica
  • 15.11.1 Pre-T Cell Technology
  • 15.11.2 AlloCAR T™
• 15.12 AlloTera Therapeutics
  • 15.12.1 Core Technology & Pipeline
• 15.13 Alpha Biopharma
  • 15.13.1 CAR-T Cell Therapy Context & Pipeline
• 15.14 Angeles Therapeutics
  • 15.14.1 Synthetic Immune Receptor-T (SIR-T™) platform
• 15.15 Anixa Biosciences
  • 15.15.1 CAR-T Program
• 15.16 Antion Biosciences SA
  • 15.16.1 Core CAR-T Technologies
  • 15.16.2 Key CAR-T Pipeline Programs
  • 15.16.3 Strategic Partnerships
• 15.17 Arbele Limited
  • 15.17.1 Arbele's CAR-T and Immuno-Oncology Approach
• 15.18 Arcellx, Inc.
  • 15.18.1 Lead Therapy (Anito-cel)
  • 15.18.2 ARC-SparX platform
  • 15.18.3 Acquisition by Gilead Sciences
• 15.19 ArsenalBio
  • 15.19.1 CITE Platform
  • 15.19.2 Key Pipeline Programs
• 15.20 A-SEEDS Co., Ltd.
  • 15.20.1 Core Focus & Business Operations
• 15.21 AstraZeneca
  • 15.21.1 Key CAR-T Assets & Strategy
  • 15.21.2 Disruptive "In Vivo" Technology
  • 15.21.3 Expansion beyond Oncology
• 15.22 Atara Biotherapeutics
  • 15.22.1 Allogeneic EBV T-Cell Platform
• 15.23 Autolus Therapeutics
  • 15.23.1 Modular CAR T-Cell Engineering
  • 15.23.2 Fast Off-Rate Binding CARs
  • 15.23.3 R&D Pipeline
• 15.24 AvenCell Therapeutics, Inc.
  • 15.24.1 Universal Switchable CAR Platform (UniCAR/RevCAR)
  • 15.24.2 UniCAR
  • 15.24.3 RevCAR
  • 15.24.4 R&D Pipeline
• 15.25 Beam Therapeutics
  • 15.25.1 Multiplex Base Editing
  • 15.25.2 BEAM-201
• 15.26 BeiCell Therapeutics
  • 15.26.1 Technology: The CiPSC Platform
  • 15.26.2 Approaches to CAR-T Cell Therapy
• 15.27 Bio4t2
  • 15.27.1 PrismCore™
  • 15.27.2 Bio-Strike™
• 15.28 BioNTech SE
  • 15.28.1 CARVac
  • 15.28.2 Product Candidates
    • 15.28.2.1 BNT211 (CLDN6 CAR-T + CARVac)
    • 15.28.2.2 BNT314/GEN1059
• 15.29 BrainChild Bio
  • 15.29.1 Multiplex Targeting
  • 15.29.2 BCB-276: The Lead Candidate
• 15.30 Bristol Myers Squibb
  • 15.30.1 Approved CAR-T Products
    • 15.30.1.1 Breyanzi (lisocabtagene maraleucel)
    • 15.30.1.2 Abecma (idecabtagene vicleucel)
  • 15.30.2 Product Candidates in ongoing Clinical Trials
• 15.31 BioAgilytix
  • 15.31.1 Key Services for CAR-T Development
• 15.32 BioOra
  • 15.32.1 Atla-cel (WZTL-002)
• 15.33 Biosceptre International Limited
  • 15.33.1 BRiDGECAR™
  • 15.33.2 R&D Pipeline
• 15.34 Cabaletta Bio
  • 15.34.1 CARTA (Chimeric Antigen Receptor T cells for Autoimmunity)
  • 15.34.2 CAAR T (Chimeric Autoantibody Receptor T cells)
  • 15.34.3 R&D Programs
• 15.35 Capstan Therapeutics
  • 15.35.1 Core Technology
  • 15.35.2 Pipeline & Focus Areas
• 15.36 Caravan Biologix
  • 15.36.1 Mini-CAR™ Technology
  • 15.36.2 Mini-VAN™ Technology
• 15.37 CARBio Therapeutics
  • 15.37.1 Core Focus & Pipeline
• 15.38 Caribou Biosciences
  • 15.38.1 chRDNA (CRISPR hybrid RNA-DNA)
  • 15.38.2 Caribou’s Clinical Programs
• 15.39 Carina Biotech
• 15.40 Caring Cross
  • 15.40.1 Core Mission & Approach
  • 15.40.2 Key Therapeutic Pipelines
  • 15.40.3 Global Collaborations
• 15.41 Caris Life Sciences
  • 15.41.1 ADAPT™ Platform
  • 15.41.2 CODEai™ Data Platform
• 15.42 CARsgen Therapeutics
  • 15.42.1 THANK-uCAR®
  • 15.42.2 CycloCAR®
  • 15.42.3 LADAR®
  • 15.42.4 CARvivo™
  • 15.42.5 CARsgen’s R&D Pipeline
• 15.43 CARTemis Therapeutics GmbH
  • 15.43.1 Core Focus & Partnerships
  • 15.43.2 TQ's CELLfinity Platform
• 15.44 Cartesian Therapeutics
  • 15.44.1 The RNA Armory® Platform
  • 15.44.2 Cartesian’s R&D Programs
• 15.45 Cell-Easy
• 15.46 Cellectis
  • 15.46.1 UCART
  • 15.46.2 Smart CAR-T
• 15.47 Cellepus Therapeutics
  • 15.47.1 Core CAR-T Development & Technology
• 15.48 Cellergy Pharma, Inc.
  • 15.48.1 IgE-Targeting CAR-T Platform Technology
• 15.49 Cellinfinity Bio
  • 15.49.1 Core Technology and Innovations
  • 15.49.2 Key Therapeutic Pipeline
• 15.50 Cellipont Bioservices
  • 15.50.1 Core Competencies in CAR-T & Cell Therapy
  • 15.50.2 Facilities & Infrastructure
  • 15.50.3 Notable CAR-T Industry Partnerships
• 15.51 Cell Therapies Pty Ltd
  • 15.51.1 Key CAR-T Services
• 15.52 Celluris
  • 15.52.1 RefuaPepCAR (RfuCAR) Technology
• 15.53 Celularity Inc.
  • 15.53.1 Placental-Derived Advantage
    • 15.53.1.1 Off-the-Shelf (Allogeneic) Capabilities
  • 15.53.2 Key Pipeline Assets
  • 15.53.3 Proprietary Technology Platform
• 15.54 Celyad Oncology SA
  • 15.54.1 shRNA-Based Allogeneic Platform
• 15.55 Century Therapeutics
  • 15.55.1 Allo-Evasion Technology
  • 15.55.2 R&D Focus
• 15.56 Chimera Bioengineering
  • 15.56.1 Core Technology & Platforms
  • 15.56.2 Focus in CAR-T Therapy
• 15.57 Chimeric Therapeutics
  • 15.57.1 CHM
  • 15.57.2 The 3rd Generation CAR-T
• 15.58 Circio Holding ASA
  • 15.58.1 How Circio's Platform Relates to CAR-T
  • 15.58.2 Strategic Partnerships & Pipeline
• 15.59 COEPTIS Therapeutics
  • 15.59.1 SNAP-CAR Technology
  • 15.59.2 How SNAP-CAR Works
    • 15.59.2.1 Key Benefits of the Technology
    • 15.59.2.2 Current Applications and Development
• 15.60 CREATE Medicines
  • 15.60.1 Key CAR-T Programs
• 15.61 CrisprBits
  • 15.61.1 CrisprBits in the Context of CAR-T Cell Therapies
• 15.62 CRISPR Therapeutics AG
  • 15.62.1 CRISPR/cas9
  • 15.62.2 Key Allogeneic CAR-T Candidates
• 15.63 Crown Bioscience
  • 15.63.1 Crown Bio's CAR-T Services
• 15.64 Curocell
  • 15.64.1 OVIS™ (Overcome Immune Suppression) Platform
  • 15.64.2 Solid Tumor CAR-T Platform
  • 15.64.3 Allogeneic (Off-the-Shelf) CAR-T Technology
  • 15.64.4 R&D Programs
• 15.65 Currus Biologics Pty Ltd
• 15.66 Cyteph Pty Ltd
  • 15.66.1 Core Technology: Cyt-ATTAC Platform
    • 15.66.1.1 CYT-AT1
• 15.67 Cytoart, Inc.
  • 15.67.1 CAR-T Related Services
• 15.68 Dispatch Bio
  • 15.68.1 Core Technology: The Flare™ Platform
  • 15.68.2 Clinical Pipeline & Partnerships
• 15.69 Dynamic Cell Therapies, Inc.
  • 15.69.1 Core Technology: Controllable CAR-T System
  • 15.69.2 Therapeutic Pipeline & Indications
• 15.70 EdiGene
  • 15.70.1 Core Technology Platforms
  • 15.70.2 Key Pipeline Programs
• 15.71 Editas Medicine
  • 15.71.1 SLEEK Technology
  • 15.71.2 Editas Medicine’s CAR-Programs
• 15.72 Elicera Therapeutics AB
  • 15.72.1 iTANK Technology
  • 15.72.2 Key Product Pipeline Candidates
• 15.73 Eli Lilly
  • 15.73.1 Strategic Acquisitions and Pipeline
  • 15.73.2 The Shift to In Vivo Technologies
• 15.74 Elpis Biopharmaceuticals
  • 15.74.1 Proprietary Technology Platforms
  • 15.74.2 Lead CAR-T Pipeline Candidates
  • 15.74.3 Key Partnerships and Clinical Trials
• 15.75 Epigenic Therapeutics
  • 15.75.1 EPIREG® Platform
  • 15.75.2 Epigenic Therapeutics & CAR-T Cell Therapy
  • 15.75.3 Core Technology Platforms
• 15.76 EsoBiotec
  • 15.76.1 The ENaBL Platform
  • 15.76.2 Pipeline & Clinical Status
• 15.77 Essen BioTech
• 15.78 Eureka Therapeutics
  • 15.78.1 CAR-T Product Candidate
• 15.79 EVA Pharma
  • 15.79.1 Moves in CAR-T Therapy
• 15.80 EXUMA Biotech
  • 15.80.1 GCAR Platform
  • 15.80.2 rPOC SC Platform
  • 15.80.3 CD3-Targeted LVV
  • 15.80.4 Tumor Metabolism Regulated (TMR) CARs
  • 15.80.5 FITNESS DRIVER
  • 15.80.6 Synthetic CAR Ligands (SCL)
  • 15.80.7 EXUMA Biotech’s R&D Pipeline
• 15.81 FastBack Bio
  • 15.81.1 M-STIM Platform
• 15.82 Fate Therapeutics
  • 15.82.1 1XX CAR Technology
  • 15.82.2 Sword and Shield™ Technology
  • 15.82.3 Alloimmune Defense Receptor (ADR) Technology
  • 15.82.4 CAR-T-Based R&D Programs
• 15.83 Fosun Pharma
  • 15.83.1 Key CAR-T Milestones and Corporate Strategy
  • 15.83.2 Patient Accessibility and Affordability
• 15.84 Galapagos NV
  • 15.84.1 Galapago’s “Pont-of-Care” CAR-T Platform
• 15.85 Gencyte Therapeutics
  • 15.85.1 PMA CAR Technology
• 15.86 Genentech Inc.
  • 15.86.1 Current CAR-T Collaborations and Focus
• 15.87 Gilead Sciences
  • 15.87.1 Key CAR-T Marketed Therapies
  • 15.87.2 Strategic Pipeline and Growth
• 15.88 Gennova Biopharmaceuticals
  • 15.88.1 Gennova's Role in CAR-T Cell Therapy
  • 15.88.2 Gennova's Strategic Direction
• 15.89 GlycoMantra
  • 15.89.1 Context in CAR-T Cell Therapy
• 15.90 GoCART Therapeutics
  • 15.90.1 Technology & Platform
• 15.91 Gracell Biotechnologies
  • 15.91.1 FasTCAR
  • 15.91.2 TrUCAR
  • 15.91.3 SMART CART
  • 15.91.4 Key Clinical Programs
• 15.92 Guangzhou Biogene Biotech Co., Ltd.
  • 15.92.1 Rapid Target Screening and Validation Platform
  • 15.92.2 Rapid Autologous CAR-T Manufacturing Platform
  • 15.92.3 Off-the-shelf CAR-T Platform
  • 15.92.4 In Vivo Modified CAR-T Platform
  • 15.92.5 Guangzhou Bio-gene’s R&D Pipeline
• 15.93 Gyala Therapeutics
  • 15.93.1 Key Pillars of Gyala Therapeutics' Focus
• 15.94 IASO Biotherapeutics
  • 15.94.1 Equecabtagene Autoleucel (eque-cel)
• 15.95 iCell Gene Therapeutics, LLC
  • 15.95.1 Compound CARs (cCARs)
  • 15.95.2 Non-Gene Editing CAR Technology
  • 15.95.3 Universal CARs (Super NK-Cells)
  • 15.95.4 Universal CARs (Super NK-Cells)
• 15.96 Immuneel Therapeutics
  • 15.96.1 Qartemi (varnimcabtagene autoleucel)
• 15.97 ImmunoACT
  • 15.97.1 NexCAR19 (Talicabtagene autoleucel)
• 15.98 Immunofoco
  • 15.98.1 Peri Cruiser® Platform
  • 15.98.2 SolidGuard
  • 15.98.3 Lentiviral-based In Vivo CAR-T Platform
  • 15.98.4 Immunofoco’s R&D Pipeline
• 15.99 Immunopharm Technology Co., Ltd.
  • 15.99.1 Core Focus & Pipeline
• 15.100 Inceptor Bio
  • 15.100.1 OUTLAST Platform
  • 15.100.2 IBT-101
• 15.101 Innovative Cellular Therapeutics
  • 15.101.2 CoupledCAR® Platform Technology
  • 15.101.3 INSTACAR™ Platform
  • 15.101.4 ARMOREDCAR™ Platform
  • 15.101.5 InvivoCAR Platform
  • 15.101.6 R&D Programs
• 15.102 Intellia Therapeutics
  • 15.102.1 Universal CAR-T
  • 15.102.2 Intellia Therapeutics’ CAR-T R&D Programs
• 15.103 Invectys, Inc.
  • 15.103.1 Core Technology & Pipeline
• 15.104 iO BiO Sciences
  • 15.104.1 Technology Platform
  • 15.104.2 Clinical & Therapeutic Focus
• 15.105 Janssen Pharmaceuticals
  • 15.105.1 Flagship Therapy: Carvykti (Cilta-cel)
  • 15.105.2 Key Partnerships and Pipeline
• 15.106 Jiangsu Pacific Meinuoke Biopharmaceuticals Co., Ltd.
  • 15.106.1 Key CAR-T Programs in the Pipeline
• 15.107 JW Therapeutics
  • 15.107.1 Key Products & Pipeline
• 15.108 Kelonia Therapeutics
  • 15.108.1 iGPS® Platform
• 15.109 Kincell Bio
  • 15.109.1 Core Focus Areas in the CAR-T Space
  • 15.109.2 Facilities and Infrastructure
• 15.110 Kiragen Bio
  • 15.110.1 KiraLOGIC Platform
• 15.111 Kite Pharma
  • 15.111.1 Yescarta® (axicabtagene ciloleucel)
  • 15.111.2 Tecartus® (brexucabtagene autoleucel)
  • 15.111.3 Bicistronic CAR-T Therapy
• 15.112 Kytopen Corp
  • 15.112.1 Kytopen's Role & Technology
  • 15.112.3 Key CAR-T Partnerships & Milestones
• 15.113 Kyverna Therapeutics
  • 15.113.1 SmarTcell™ platform
  • 15.113.2 Ingenui-T™ Manufacturing Platform
• 15.114 Legend Biotech Corporation
  • 15.114.1 Core Technology Platforms
    • 15.114.2.1 CARVYKTI® (ciltacabtagene autoleucel)
  • 15.114.3 Pipeline Candidates
• 15.115 Leman Biotech Co., Ltd.
  • 15.115.1 Clinical Breakthroughs
  • 15.115.2 Core Technology & Partnerships
• 15.116 Leucid Bio
  • 15.116.1 Lateral CAR-T Platform
  • 15.116.2 Pipeline Lead Asset: LEU011
• 15.117 Liminatus Pharma
  • 15.117.1 Core Therapeutics & Pipeline
• 15.118 Link Cell Therapies
  • 15.118.1 Logic-Gated CAR-T
• 15.119 Luminary Therapeutics
  • 15.119.1 Technology
• 15.120 Lyell Immunopharma
  • 15.120.1 Key Reprogramming Technologies
  • 15.120.2 Lyell Immunopharma's R&D Programs
• 15.121 March Biosciences, Inc.
  • 15.121.1 Pipeline & Technology
• 15.122 MaxCyte, Inc.
  • 15.122.1 The ExPERT GTx® system
  • 15.122.2 Company Focus and Core Technology
  • 15.122.3 Strategic Impact of ExPERT GTx on CAR-T and Cell Therapy
  • 15.122.4 Industry Adoption of ExPERT GTx
• 15.123 MedTherapy Biotech
  • 15.123.1 Core Services & Platforms
• 15.124 Miltenyi Biomedicine GmbH
  • 15.124.1 CliniMACS Prodigy® system
  • 15.124.2 Miltenyi Biotec’s CAR-T Product Pipeline
• 15.125 Minerva Biotechnologies
• 15.126 Mustang Bio
  • 15.126.1 Key Clinical Programs
  • 15.126.2 Proprietary Manufacturing Facility
• 15.127 Nexcella, Inc.
  • 15.127.1 NXC-201
• 15.128 Noile-Immune Biotech Inc.
  • 15.128.1 PRIME Technology
  • 15.128.2 Key Pipeline Candidates
• 15.129 Novartis International AG
  • 15.129.1 T-Charge™ Platform
  • 15.129.2 Kymriah® (tisagenlecleucel)
• 15.130 Novatim Immune Therapeutics
  • 15.130.1 The IRAE Bifunctional antibody Platform
  • 15.130.2 Nanoantibody Screening Platform
  • 15.130.3 K2 CAR-T Platform
  • 15.130.4 Novatim’s R&D Pipeline
• 15.131 OneChain Immunotherapeutics
• 15.132 OncoC4, Inc.
  • 15.132.1 Role in CAR-T Cell Therapy
• 15.133 Optieum Biotechnologies
  • 15.133.1 Eumbody System™
• 15.134 OriCell Therapeutics
  • 15.134.1 Key Products & Pipeline
• 15.135 Orna Therapeutics
  • 15.135.1 The Circular RNA (oRNA) Platform
  • 15.135.2 Primary Target Areas
• 15.136 Outpace Bio
  • 15.136.1 OUTSMART™ Technology
  • 15.136.2 OUTLAST™ Technology
  • 15.136.3 OUTSPACERS™ Technology
  • 15.136.4 OUTSAFE™ Technology
  • 15.136.5 OUTDRIVE™ Technology
  • 15.136.6 R&D Programs
• 15.137 PeproMene Bio
  • 15.137.1 Core Technologies
    • 15.137.1.1 BAFFR-CAR T cells (PMB-CT01)
    • 15.137.1.2 BAFFR CAR-NK Cells
    • 15.137.1.3 BAFFR Bispecific T Cell Engager (BiTE)
    • 15.137.1.4 High-Polyfunctionality CAR Platform
  • 15.137.2 Key CAR-T-Based Clinical Trials
• 15.138 Poseida Therapeutics
  • 15.138.1 Technologies
  • 15.138.2 piggyBac™ DNA Modification System
  • 15.138.3 Cas-CLOVER™ Site-Specific Gene Editing
  • 15.138.4 Allogeneic (TSCM)-Rich Platform
  • 15.138.5 Booster Molecule Technology
    • 15.138.5.1 Solid Tumor & Dual CAR Capabilities
  • 15.138.6 Key Pipeline Programs
• 15.139 Precigen
  • 15.139.1 Core CAR-T Technologies
  • 15.139.2 Key Clinical Programs
• 15.140 Precision Biosciences
  • 15.140.1 Key Features of Precision's CAR-T Platform
• 15.141 Prescient Therapeutics Ltd
  • 15.141.1 OmniCAR Platform
  • 15.141.2 CellPryme-M
  • 15.141.3 CellPryme-A
  • 15.141.4 PTX-100
• 15.142 Priothera, Ltd.
  • 15.142.1 Role in CAR-T and Cellular Therapy
• 15.143 ProMab Biotechnologies, Inc.
  • 15.143.1 Core CAR-T Custom Services
• 15.144 PromiCell
  • 15.144.1 IL-18 Cytokine Armoring (SAVVY-IL18 Platform)
• 15.145 Regeneron
• 15.146 Roche Group
  • 15.146.1 Acquisitions & Strategic Direction
  • 15.146.2 Key CAR-T Programs
  • 15.146.3 Target Indications
• 15.147 Sana Biotechnology
  • 15.147.1 Key CAR-T-Based Technologies
  • 15.147.2 Hypoimmune (HIP) Platform (Allogeneic)
  • 15.147.3 Fusogen Platform
  • 15.147.4 Ex Vivo Cell Engineering
• 15.148 Senti Bio
  • 15.148.1 Core Technology: Gene Circuits & Logic Gates
  • 15.148.2 Pipeline & Clinical Focus
  • 15.148.3 Clinical Status & Regulatory Designations
• 15.149 Shenzhen MagicRNA Biotechnology Co., Ltd.
  • 15.149.1 Technology Platform
  • 15.149.2 Product Pipeline & Therapeutics
• 15.150 Shenzhen Pregene Biopharma Co., Ltd.
  • 15.150.1 Key CAR-T Program
  • 15.150.2 PRG-1801 (anti-BCMA CAR-T)
• 15.151 Simnova Biotherapeutics
  • 15.151.1 BiTE-Armed CAR-T Cells
• 15.152 Strand Therapeutics
  • 15.152.1 In Vivo Cell Programming
  • 15.152.2 The SignalLock and SignalPath Systems
  • 15.152.3 Repeat Dosing and Safety
  • 15.152.4 Therapeutic Indications
• 15.153 Synlico, Inc.
• 15.154 TC Biopharm
  • 15.154.1 Gamma Delta T (GDT) Cell Platform
  • 15.154.2 Co-Stim CAR-T Platform
  • 15.154.3 CryoTC Technology
  • 15.154.4 ImmuniCAR® Platform
  • 15.154.5 TC Biopharm’s Clinical Programs
• 15.155 T-CURX GmbH
  • 15.155.1 Sleeping Beauty
  • 15.155.2 Key CAR-T Product Candidate Pipeline
• 15.156 Terumo BCT
  • 15.156.1 Quantum Flex
• 15.157 TG Therapeutics
  • 15.157.1 CAR-T Pipeline & Focus
• 15.158 Thermo Fisher Scientific
  • 15.158.1 Core Tools and Instrumentation for CAR-T Workflows
  • 15.158.2 Media, Reagents, and Analytics
  • 15.158.3 End-to-End CDMO and CRO Services
• 15.159 Tikva Allocell Pte Ltd
  • 15.159.1 Core Technology & Pipeline
• 15.160 TriArm Therapeutics
  • 15.160.1 FIT™ (Fast-In-Time)
  • 15.160.2 FlexTune™
  • 15.160.3 OppoTAGs (Adaptors) Technology
  • 15.160.4 CD30+ FineTune™ Technology
  • 15.160.5 CD3ε FlowTune™ Technology
  • 15.160.6 Key Clinical Programs
• 15.161 T-Maximum Pharmaceutical
  • 15.161.1 Core Focus & Pipeline
• 15.162 Ucello Therapeutics
  • 15.162.1 CBT-X20™ Technology Platform
  • 15.162.2 Key Product Candidates
• 15.163 Umoja Biopharma
  • 15.163.1 VivoVec™ In Vivo Delivery Platform
  • 15.163.2 RACR™/CAR In Vivo Cell Expansion/Control Platform
  • 15.163.3 TumorTag™ Targeting Platform
  • 15.163.4 Umoja’s R&D Programs
• 15.164 Vector BioMed, Inc.
  • 15.164.1 The LENTIVERSE Platform
  • 15.164.2 Context and Global Impact in CAR-T
    • 15.164.2.1 Regional Deployment in India
• 15.165 Verismo Therapeutics
  • 15.165.1 KIR-CAR Platform
  • 15.165.2 R&D Programs
• 15.166 Vittoria Biotherapeutics
  • 15.166.1 Senza5™ Technology
• 15.167 Waypoint Bio
  • 15.167.1 Core Technology & Approach
  • 15.167.2 Key Therapeutic Programs
• 15.168 Wugen, Inc.
  • 15.168.1 Wugen's CAR-T Program
• 15.169 Xcell Biosciences
  • 15.169.1 AVATAR™ Platform
  • 15.169.2 AVATAR Odyssey™ (Research System)
  • 15.169.3 AVATAR Ai™ (Software)
• 15.170 Xenetic Biosciences, Inc.
  • 15.170.1 Key CAR-T Initiatives
  • 15.170.2 Clinical & Strategic Milestones
• 15.171 Xyphos Biosciences
  • 15.171.1 convertibleCAR-T™
• 15.172 YolTech Therapeutics
  • 15.172.1 Core Focus

INDEX OF FIGURES

• FIGURE 2.1: The Schematic Diagram of CAR Structure
• FIGURE 5.1: Number of CAR-T Cell Therapy Patent Filings, 2010 to 2025
• FIGURE 5.2: Patent Filings for Autologous & Allogeneic CAR-Ts Compared, 2015-2025
• FIGURE 5.3: Patent Filings by CAR-T Generation Type
• FIGURE 5.4: Pantent Filings for Blood Cancers & Solid Tumors Compared, 2015-2025
• FIGURE 5.5: CAR-T Patent Filings for Autoimmine Diseases
• FIGURE 5.6: Patent Filings for In Vivo CAR-T Cell Therapies
• FIGURE 5.7: Distribution of Filed CAR-T Patents by Jurisdiction
• FIGURE 5.8: Macro Global Patent Portfolio Distribution
• FIGURE 6.1: The Bedrock Ascent of CAR-T Research Publications, 2010-2025
• FIGURE 6.2: The Allogeneic Ascent over Autologous CAR-T PubMed.gov Publications
• FIGURE 6.3: The Solid Tumor Breakthrough in CAR-T Research Publications
• FIGURE 6.4: PubMed Papers on CAR-T In Situ Revolution
• FIGURE 6.5: PubMed Papers CAR-T’s New Frontier of Autoimmune Diseases
• FIGURE 7.1: Percent Share of CAR-T Clinical Trials by CAR Generation Type
• FIGURE 7.2: Percent Share of CAR-T Clinical Trials by Co-stimulatory Domains
• FIGURE 7.3: Percent Share of CAR-T Clinical Trials by Target Disease
• FIGURE 7.4: Global Share of CAR-T Clinical Trials by Sponsor Type
• FIGURE 7.5: Percent Share of Top 5 Hospitals & Clinical Centers in CAR-T Clinical Trials
• FIGURE 7.6: Percent Share of Top 7 Companies in CAR-T Clinical Trials
• FIGURE 7.7: Percent Share of CAR-T Clinical Trials by Top 7 Academic Institutions
• FIGURE 7.8: Percent Share of CAR-T Clinical Trials’ Study Phases
• FIGURE 7.9: Funders of CAR-T Clinical Trials
• FIGURE 13.1: Sales Revenue Generated by FDA-Approved CAR-T Therapies, 2018-2025
• FIGURE 13.2: Sales Revenue by CAR-T Cell Therapies Approved in China, 2022-2025
• FIGURE 13.3: Sales Revenue Generated by CAR-T Therapies in India, 2023-2025
• FIGURE 13.4: Estimated Global Market for CAR-T Cell Therapies by Geography, 2025-2035
• FIGURE 13.5: Estimated Global Market for CAR-T Cell Therapies by Target Antigen, 2025-2035
• FIGURE 13.6: Percent Share of CAR-T Market by Approved Indication, 2025
• FIGURE 13.7: Percent Share of CAR-T Market by Sub-Types of Lymphoma, 2025
• FIGURE 13.8: Percent Share of CAR-T-based Multiple Myeloma Market by Sub-Types
• FIGURE 13.9: CAR-T Market for Leukemia Indication by Sub-Type
• FIGURE 14.1: The Percent Shares of Autologous & Allogeneic CAR-T Companies
• FIGURE 14.2: Percent Share of CAR-T Companies by Generation Type

INDEX OF TABLES

• TABLE 2.1: Differentiating Features of the Five Generations of CAR-T Cells
• TABLE 2.2: Research Institutions involved in Early Experiments using 1st Generation CAR-
• TABLE 2.3: Companies utilizing 2nd Generation CAR-T in their Product Portfolio
• TABLE 2.4: Companies Utilizing 3rd Generation CAR-T
• TABLE 2.5: Companies utilizing 4th Generation CAR-T
• TABLE 2.6: Companies Utilizing 5th Generation CAR-T
• TABLE 2.7: Companies Developing In Vivo CAR-T Cell Therapies
• TABLE 2.8: Top Companies in Allogeneic CAR-T Space
• TABLE 2.9: Companies Developing Armored CAR-T Products
• TABLE 2.10: Companies Developing Logic-Gated CAR-T Cells
• TABLE 3.1: Timeline of CAR-T Cell Therapy Development, 1989-2026
• TABLE 3.1: (CONTINUED)
• TABLE 4.1: Prominent All-in-One Integrated Instruments for CAR-T Manufacture
• TABLE 4.2: Prominent Modular & Specialized Expansion Bioreactors
• TABLE 4.3: Cost Breakdown Matrix (Per-Dose CAR-T Manufacturing COGS)
• TABLE 4.4: Cost Breakdown Matrix (Per-Dose Allogeneic COGS)
• TABLE 5.1: Cost of Filing and Securing a CAR-T Therapy Patent
• TABLE 5.2: Licensing Cost of CAR-T Cell Therapy Patents
• TABLE 5.3: Top 10 CAR-T Cell Therapy Licensing Deals
• TABLE 5.4: Top 20 CAR-T Cell Therapy Patent Jurisdictions
• TABLE 5.5: Top 20 CAR-T Cell Therapy Patent Applicants
• TABLE 5.6: Top 20 CAR-T Cell Therapy Patent Inventors
• TABLE 5.7: Top 20 CAR-T Cell Therapy Patent Owners
• TABLE 5.8: Legal Status of CAR-T Cell Therapy Filed Patents
• TABLE 5.9: Top 20 Granted CAR-T Cell Therapy Patents
• TABLE 5.9: (CONTINUED)
• TABLE 7.1: Cost Breakdown by Clinical Trial Phase
• TABLE 8.1: Venture Capital Funding in CAR-T Sector, 2024-2026
• TABLE 8.2: CAR-T Collaboration Deals, 2023- July, 2026
• TABLE 8.3: Merger & Acquisition Deals in CAR-T Therapy Sector, 2024-2026
• TABLE 9.1: Globally Approved CAR-T Cell Therapies
• TABLE 9.2: Dates of Kymriah’s Approvals by Regions/Countries
• TABLE 9.3: Development Pipeline of Kymriah (tisagenlecleucel)
• TABLE 9.4: Cost Breakdown at Kymriah Certified Centers in the U.S.
• TABLE 9.5: Kymriah’s Competitors
• TABLE 9.6: Yescarta’s Approval by Region/Country
• TABLE 9.7: Development Timeline of Yescarta
• TABLE 9.8: Other Therapies Competing with Yescarta
• TABLE 9.9: Tecartus’ Approval Dates by Region/Country
• TABLE 9.10: Approval History of Tecartus (brexucabtagene autoleucel)
• TABLE 9.11: Competing Therapies with Tecartus
• TABLE 9.12: Dates of Approval of Breyanzi by Region/Country
• TABLE 9.13: Development Timeline of Breyanzi
• TABLE 9.14: Breyanzi’s Competitors
• TABLE 9.15: Dates of Approval of Abecma by Region/Country
• TABLE 9.16: Approval History of Abecma
• TABLE 9.17: Abecma’s Competitors
• TABLE 9.18: Dates of Approval of Carvykti by Region/Country
• TABLE 9.19: Development Timeline of Carvykti
• TABLE 9.20: Carvykti’s Competitors
• TABLE 9.21: Development Timeline of Aucatzyl
• TABLE 9.22: Competing Therapies for Aucatzyl
• TABLE 9.23: Development Timeline of Carteyva
• TABLE 9.24: Competing Therapies for Carteyva
• TABLE 9.25: Yikaida’s Development Timeline
• TABLE 9.26: Competing Therapies with Yikaida
• TABLE 9.27: Development Timeline for Zevor-cel
• TABLE 9.28: Approved Competing Therapies against Zevor-cel
• TABLE 9.29: Development Timeline of Yorwida
• TABLE 9.30: Other Approved Competing Therapies against Yorwida
• TABLE 9.31: Development Timeline of Fucaso
• TABLE 9.32: Approved CAR-T & Non CAR-T Therapies with Fucaso
• TABLE 9.33: Development Timeline of Satri-cel
• TABLE 9.34: Approved Non-CAR-T Competing Therapies for Satri-cel
• TABLE 9.35: Development Timeline of Qartemi
• TABLE 9.36: Approved CAR-T & Non-CAR-T Competing Therapies
• TABLE 9.37: Development Timeline of NexCAR19
• TABLE 11.1: Global Cost Breakdown for CAR-T Therapy by Medical Tourism Destination
• TABLE 11.2: Manufacturing Cost of CAR-T Cell Therapy
• TABLE 11.3: Cost of Developing CAR-T Therapy from Discovery to Marketing Approval
• TABLE 11.4: Cost of Developing CAR-T Therapy from Academics to Spinouts
• TABLE 11.5: Global CAR-T Treatment Cost Comparison
• TABLE 11.6: Total Treatment Cost for CAR-T Cell Therapies in the U.S.
• TABLE 11.7: Total CAR-T Treatment Cost in Europe
• TABLE 11.8: Total CAR-T Treatment Cost in Japan
• TABLE 11.9: Total CAR-T Treatment Cost in South Korea
• TABLE 11.10: Total CAR-T Treatment Cost in Australia
• TABLE 11.11: Total CAR-T Treatment Cost in China
• TABLE 11.12: Total CAR-T Treatment Cost in India
• TABLE 12.1: Key Therapeutic Targets and Mechanisms of CAR-T in the Emerging Scenario
• TABLE 12.2: Overview of Treatment Options for Lymphoblastic Leukemia
• TABLE 12.3: Overview of Treatment Options for B-Cell Lymphomas
• TABLE 12.4: Overview of Treatment Options for Multiple Myeloma
• TABLE 13.1: Sales Revenue Generated by FDA-Approved CAR-T Cell Therapies, 2018-2025
• TABLE 13.2: Sales Revenue by CAR-T Cell Therapies Approved in China, 2022-2025
• TABLE 13.3: Sales Revenue Generated by CAR-T Cell Therapies Approved in India
• TABLE 13.4: Estimated Global Market for CAR-T Cell Therapies by Geography, 2025-2035
• TABLE 13.5: Revenue Generated by CD19 & BCMA Targeting CAR-T Cell Therapies as of 2025
• TABLE 13.6: Estimated Global Market for CAR-T Cell Therapies by Target Antigen, 2025-2035
• TABLE 13.7: Indications Addressed by CAR-T Cell Therapy
• TABLE 14.1: Leading Companies with Second-Generation CAR-Ts
• TABLE 14.2: Leading Companies with Next Generation CAR-Ts
• TABLE 14.3: Comparison of Second Generation & Next-Generation CAR-Ts
• TABLE 14.4: Companies developing Autologous & Allogeneic CAR-T Therapies
• TABLE 14.5: CAR-T Companies by Gene Editing/Modification Technology
• TABLE 14.6: CAR-T Companies by Targeting and Logic Gate Technology
• TABLE 14.7: CAR-T Companies by Indication Specialization
• TABLE 14.8: CAR-T Companies by Production model
• TABLE 15.1: 4immune Therapeutics’ R&D Programs
• TABLE 15.2: A2 Biotherapeutics’ RD Pipeline
• TABLE 15.3: AbClon’s CAR-T Product Candidates
• TABLE 15.4: AbelZeta’s R&D Pipeline
• TABLE 15.5: Aleta’s Product Candidates
• TABLE 15.6: Allogene’s AlloCAR-T Product Pipeline
• TABLE 15.7: Atara Bio’s Next-generation allogeneic CAR-T programs
• TABLE 15.8: Autolus Therapeutics’ R&D Pipeline
• TABLE 15.9: AvenCell’s R&D Pipeline
• TABLE 15.10: Cabaletta Bio’s R&D Pipeline
• TABLE 15.11: Carina Biotech’s Product Pipeline
• TABLE 15.12: CARsgen’s R&D Pipeline
• TABLE 15.13: Cartesian’s R&D Programs
• TABLE 15.14: Cellectis’ CAR-T cell Pipeline
• TABLE 15.15: Chimeric Therapeutics’ Product Pipeline
• TABLE 15.16: Curocell’s R&D Programs
• TABLE 15.17: Essen BioTech’s CAR-T-Based R&D Pipeline
• TABLE 15.18: EXUMA Biotech’s R&D Pipeline
• TABLE 15.19: Fate Therapeutics’ CAR-T-Based R&D Programs
• TABLE 15.20: Galapago’s R&D Pipeline for CAR-T
• TABLE 15.21: Guangzhou Bio-gene’s R&D Pipeline
• TABLE 15.22: IASO’s Ongoing Clinical Programs using CAR-T
• TABLE 15.23: iCell Gene Therapeutics’ R&D Pipeline
• TABLE 15.24: Immuneel’s Products in Development
• TABLE 15.25: Immunofoco’s R&D Pipeline
• TABLE 15.26: Innovative Cellular Therapeutics’ R&D Programs
• TABLE 15.27: Kelonia Therapeutics’ R&D Programs
• TABLE 15.28: Kiragen Bio’s R&D Programs
• TABLE 15.29: Kyverna Therapeutics’ R&D Programs
• TABLE 15.30: Luminary’s R&D Programs
• TABLE 15.31: Lyell Immunopharma’s R&D Programs
• TABLE 15.32: Miltenyi Biotec’s CAR-T Product Pipeline
• TABLE 15.33: Minerva Biotechnologies’ Autologous CAR-T Product Pipeline
• TABLE 15.34: Novatim’s R&D Pipeline
• TABLE 15.35: Optieum Biotechnologies’ Product Pipeline
• TABLE 15.36: Outpace Bio’s R&D Programs
• TABLE 15.37: PromiCell’s R&D Programs
• TABLE 15.38: Sana Biotechnologies’ R&D Pipeline
• TABLE 15.39: Simnova Biotherapeutics’ CAR-T R7D Pipeline
• TABLE 15.40: TriArm’s Clinical Programs
• TABLE 15.41: Umoja Biopharma’s R&D Programs
• TABLE 15.42: Vittoria Therapeutics’ R&D Pipeline